Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b – Slideshow

Teva Pharmaceutical Industries Limited (TEVA) Discusses Anti-IL-15 Antibody Phase Ib 24-Week Efficacy Results in Vitiligo and Planned Advancement to Phase 2b – Slideshow#Teva #Pharmaceutical #Industries #Limited #TEVA #Discusses #AntiIL15 #Antibody #Phase #24Week #Efficacy #Results #Vitiligo #Planned #Advancement #Phase #Slideshow